Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES

Advanced Blood Test Detects and Analyzes Circulating Tumor Cells

By Labmedica International staff writers
Posted on 13 Feb 2012
An advanced blood test detects and analyzes circulating tumor cells (CTCs) from cancer patients.

The new test, called high definition CTC (HD-CTC), labels cells in a patient's blood sample in a way that distinguishes possible CTCs from ordinary red and white blood cells. A digital microscope and an image-processing algorithm are used to isolate the suspect cells with sizes and shapes (morphologies) unlike those of healthy cells. A pathologist can examine the images of the suspected CTCs to eliminate false positives and note their morphologies.

Scientists from The Scripps Research Institute (TSRI; La Jolla, CA, USA), Scripps Health, and collaborating cancer physicians successfully demonstrated the effectiveness of the blood test. Five new studies resulted from the collaboration and demonstrated the new test's accuracy and effectiveness for a number of different cancer types. The studies also began to explore the utility of the technology for diagnosing and monitoring patients and improving cancer research in the lab.

"It is a next-generation technology," said Scripps' Associate Prof. Peter Kuhn, PhD, senior investigator of the new studies and primary inventor of the high-definition blood test. "It significantly boosts our ability to monitor, predict, and understand cancer progression, including metastasis, which is the major cause of death for cancer patients."

Whereas other tests for CTCs typically use enrichment steps in which suspected CTCs are concentrated--methods that can inadvertently exclude some types of CTCs--the new studies show HD-CTC works well as a no-cell-left-behind process and enables a more complete analysis.

Prof. Kuhn emphasized that the basic setup can be easily modified with different cell-labeling and image-processing techniques. He and his colleagues will study the use of HD-CTC as a potential screening test and develop it further for use in clinical monitoring and cancer research. Prof. Kuhn has founded a San Diego-based biotechnology company, Epic Sciences, Inc. (CA, USA) to develop HD-CTC commercially for companion diagnostic products in personalized cancer care.

The studies were published in the February 2012 edition of the journal Physical Biology.

Related Links:
The Scripps Research Institute
Epic Sciences



MEDLAB Asia
CELLAVISION AB
KARL HECHT GMBH & CO KG
PERIPHERAL VISIONS INC

Channels

Clinical Chemistry

view channel
Image: UniCel DxC 800 Synchron Clinical Systems (Photo courtesy of Beckman Coulter).

Routine Blood Glucose Value Correlates with Diabetes Risk

Random glucose values obtained during routine blood tests are often overlooked, but could provide valuable insight into whether someone is at risk for having type 2 diabetes. Random Blood Glucose (RBG)... Read more

Genetic Tests

view channel
Image: Histopathology of tuberculoid leprosy in a skin section (Photo courtesy Dr. D.S. Ridley, Wellcome Images).

Genes Discovered Influence Risk of Developing Leprosy

Leprosy, a chronic dermatological and neurological disease, is caused by infection with Mycobacterium leprae, and its manifestation, progression and prognosis are strongly associated with the proficiency... Read more

Hematology

view channel
Image: Plastic bag containing 0.5 to 0.7 liters of packed red blood cells in citrate, phosphate, dextrose, and adenine (CPDA) solution (Photo courtesy of Fresenius HemoCare).

Transfusion Protocols Compared After Cardiac Surgery

Unnecessary blood transfusions may increase healthcare costs both directly, because blood is an increasingly scarce and expensive resource, and indirectly due to the complications associated with transfusion.... Read more

Industry News

view channel

Sequencing-Based Testing Sector Already Highly Competitive

As next-generation sequencing (NGS) reaches the clinical laboratory, a new analysis by Kalorama Information (New York, NY, USA) finds that small reference laboratories as well as over 50 companies now offer sequencing-based testing through their own CLIA-certified laboratories, some of which offer a wide range of tests.... Read more
 

Events

06 Apr 2015 - 08 Apr 2015
07 Apr 2015 - 09 Apr 2015
13 Apr 2015 - 16 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.